Coherus Biosciences Posts Quarterly Loss Above Expectations – LOQTORZI Revenue Targets Confirmed
This article was created with the help of artificial intelligence.
Key Takeaways
- Coherus Biosciences posted a quarterly loss of $0.25 per share in Q1 2026, which was 39 percent above analyst expectations of $0.18 per share.
- Loss per share improved 28 percent versus the year-ago quarter, when the loss was $0.35 per share.
- The company expects increasing revenue for LOQTORZI, its drug for treating nasopharyngeal carcinoma, in the remainder of 2026.
- Coherus Biosciences is preparing several clinical data releases from its oncology pipeline expected in the second half of 2026.
- The biopharmaceutical company is increasingly focusing on innovative cancer therapies following its successful biosimilars past.
Coherus Biosciences (NASDAQ: CHRS) reported on May 11, 2026 for the first quarter a loss of $0.25 per share, missing consensus estimates by 39 percent of $0.18 per share. In the year-ago quarter, the company had reported a loss of $0.35 per share – losses thus decreased by 28 percent. The Redwood City, California-based biotechnology company also fell short of analyst expectations on revenue.
Outlook on LOQTORZI Revenue Development
Despite disappointing quarterly results, management showed optimism during the earnings call for the coming months. Coherus Biosciences expects increasing revenue for LOQTORZI for the remainder of 2026. LOQTORZI is a drug for the treatment of nasopharyngeal carcinoma – a type of cancer that develops in the nasopharynx and occurs more frequently in Southeast Asia and South China.
The company is also preparing for several clinical data releases in its oncology pipeline expected in the second half of 2026. These data could influence the company's further strategic direction and provide important insights into the efficacy of therapies in development.
Development Versus Year-Ago Quarter
The comparison to the prior year shows an improvement in the loss situation: While Coherus Biosciences lost $0.35 per share in the first quarter 2025, the company reduced the loss to $0.25 per share in the first quarter 2026. Nevertheless, the company missed analyst expectations, which had forecast a smaller loss of $0.18 per share.
Company Background
Coherus Biosciences is a biopharmaceutical company focused on the development and commercialization of oncology therapies. The company originally became known through biosimilars – biotech-manufactured copycat products of already-approved biologics – but is increasingly focusing on innovative cancer therapies. The portfolio includes both approved medications and products in various stages of development.
Upcoming quarterly results and clinical data releases will show whether the company can meet its forecast for revenue growth in LOQTORZI and how its pipeline projects develop.